Skip to content

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00005900
Enrollment
10
Registered
2000-06-05
Start date
1999-08-31
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenoleukodystrophy, Fucosidosis, Gaucher's Disease, Globoid Cell Leukodystrophy, I Cell Disease, Mannosidosis, Metachromatic Leukodystrophy, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Niemann-Pick Disease, Pulmonary Complications, Wolman Disease

Keywords

Gaucher's disease, I cell disease, Niemann-Pick disease, Wolman disease, adrenoleukodystrophy, disease-related problem/condition, fucosidosis, genetic diseases and dysmorphic syndromes, globoid cell leukodystrophy, inborn errors of metabolism, mannosidosis, metachromatic leukodystrophy, mucopolysaccharidosis, mucopolysaccharidosis I, mucopolysaccharidosis VI, oncologic disorders, pulmonary complications, rare disease, sphingolipidoses

Brief summary

OBJECTIVES: I. Evaluate bronchoalveolar lavage fluid and serum obtained from pediatric patients with storage disorders prior to allogeneic hematopoietic stem cell transplantation (HSCT) for the presence of proinflammatory cytokines and for the production of nitric oxide by alveolar macrophages to identify possible risk factors for pulmonary complications. II. Investigate the underlying mechanism for the development of significant pulmonary complications in these patients during HSCT. III. Evaluate bronchoalveolar lavage fluid and serum obtained from these same patients at the time a pulmonary complication develops post-HSCT, or at 60 days post-HSCT if there has been no pulmonary complications.

Detailed description

PROTOCOL OUTLINE: Patients undergo bronchoscopy with bronchoalveolar lavage (BAL) prior to allogeneic hematopoietic stem cell transplantation (HSCT). ELISA assays for cytokines are performed. Patients are followed post-HSCT for the development of transplant related pulmonary complications. A repeat bronchoscopy with BAL is performed at the time pulmonary complications develop or at day 60 post-HSCT if no complications develop. Cytokine assays are repeated.

Interventions

None listed

Sponsors

Fairview University Medical Center
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of an inborn error of metabolism eligible for allogeneic hematopoietic stem cell transplantation on protocol UMN-MT-1995-01

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026